Dipeptidyl Peptidases and E3 Ligases: Coordinated Control of Protein Stability via the N-degron Pathway

Study Background and Research Question

The regulation of protein stability is fundamental to cellular homeostasis, particularly for secretory proteins that must be accurately targeted and folded. The ubiquitin-proteasome system (UPS) achieves this specificity through the recognition of N-terminal degrons—short motifs that tag proteins for degradation. While E3 ubiquitin ligases are known to recognize these signals, the mechanistic interplay between proteases that expose degrons and the ligases that act upon them has remained poorly understood. The recent study by Shimshon et al. (J. Cell Biol. 2024) addresses this knowledge gap by investigating how dipeptidyl peptidases (DPP8/9) and E3 ligases of the N-degron pathway cooperate in protein quality control.

Key Innovation from the Reference Study

The central innovation of this work lies in uncovering a cooperative mechanism between dipeptidyl peptidases and N-degron pathway E3 ligases that governs the degradation of proteins bearing a proline at the third N-terminal position (P+3). The authors systematically demonstrate that DPP8/9 activity is critical for exposing a previously hidden N-degron motif within the signal peptides of secretory proteins. When translocation to the endoplasmic reticulum fails, this motif is rendered accessible, allowing UBR family E3 ligases to target the mislocalized proteins for proteasomal degradation. This cooperation ensures the removal of potentially harmful proteins that would otherwise accumulate in the cytoplasm, highlighting a proteostasis safeguard that links protease activity directly to the N-degron pathway.

Methods and Experimental Design Insights

To dissect the interplay between proteases and E3 ligases, the authors employed a robust N-terminome library, which enables systematic monitoring of protein stability across various engineered N-terminal sequences. Through genetic perturbations and loss-of-function screens, they identified DPP8/9 as key regulators of substrates containing a P+3 motif. In parallel, they confirmed the involvement of UBR-family E3 ligases, which are primary components of the Arg/N-degron pathway. Importantly, the study leveraged secretory protein models with well-characterized signal peptides to illustrate how this mechanism operates under physiological and stress conditions, such as translocation failure.

Core Findings and Why They Matter

The study's principal findings are as follows:

• P+3 N-degron motifs confer instability: Proteins with a proline at the third N-terminal position are prone to degradation, especially when upstream protease activity is intact.
• DPP8/9 and UBR ligase cooperation: Loss of DPP8/9 stabilizes P+3-bearing substrates, indicating that dipeptidyl peptidase activity is necessary to expose degrons recognized by UBR E3 ligases.
• Secretory protein specificity: The mechanism is particularly relevant to secretory proteins, which often harbor a 'built-in' N-degron within their signal peptide. Upon translocation failure, DPP8/9 exposes this motif, targeting the protein for degradation.

This cooperative pathway is significant because it links the fidelity of protein trafficking with cytosolic protein quality control. The process prevents the accumulation of mislocalized secretory proteins, which could otherwise disrupt cellular function or trigger proteotoxic stress. These insights advance our understanding of how cells maintain proteostasis and may inform future research into diseases characterized by protein misfolding or mistargeting.

Comparison with Existing Internal Articles

Several internal articles focus on the role of dipeptidyl peptidase inhibitors, particularly Talabostat mesylate (PT-100), in cancer research and tumor microenvironment modulation. For example, the article "Talabostat mesylate: DPP4 and FAP Inhibition in Cancer Biology" discusses how DPP4 and FAP inhibition modulates T-cell immunity and induces hematopoiesis via G-CSF. While these internal resources primarily address cancer biology applications—such as "Talabostat Mesylate (PT-100): Applied Protocols in Tumor Microenvironment Research"—the reference study by Shimshon et al. broadens the mechanistic context by elucidating how dipeptidyl peptidase activity interfaces with fundamental protein degradation machinery. This theoretical framework helps explain why specific inhibitors of DPP4 family enzymes, such as Talabostat mesylate, can have profound effects not only on immune modulation but potentially on protein quality control and turnover, especially in FAP-expressing tumor settings.

Limitations and Transferability

While the study provides compelling mechanistic insights, its findings are primarily derived from engineered protein libraries and genetic perturbation models. The direct physiological relevance in complex tissues or disease states, such as cancer or neurodegeneration, remains to be fully validated. Additionally, while DPP8/9 were the focus, the broader family of dipeptidyl peptidases (including DPP4 and FAP) may have overlapping or distinct roles in N-degron exposure, as suggested by cancer research utilizing specific inhibitors. Caution is warranted when extrapolating these results to settings where multiple DPP activities or alternative degron pathways could be operative.

Protocol Parameters

• N-terminome library screening: Use engineered constructs with defined N-terminal sequences to assess stability under wild-type and DPP8/9-deficient conditions.
• Genetic perturbation: Employ CRISPR/Cas9 knockout or RNA interference to selectively disrupt DPP8/9 or UBR-family E3 ligases.
• Secretory protein modeling: Introduce signal peptide variants into cell lines to monitor degradation following induced translocation failure.
• Proteasome inhibition controls: Use MG132 or similar compounds to confirm proteasome-dependent turnover.
• When translating to cancer models: Consider FAP-expressing cell lines or primary tissues as relevant systems for DPP4/FAP inhibitor testing, referencing workflow suggestions from internal protocol guides.

Research Support Resources

Researchers aiming to probe the role of dipeptidyl peptidase activity in protein stability or tumor microenvironment modulation can employ chemical inhibitors as investigative tools. Talabostat mesylate (SKU B3941) is a well-characterized, orally active inhibitor of DPP4 and FAP, suitable for studies on DPP-mediated protein turnover, immune response modulation, and hematopoiesis induction via G-CSF. The specificity and solubility profile of Talabostat mesylate, as described in the product information, facilitate reproducible workflows in both in vitro and in vivo models. For detailed protocols and troubleshooting advice, APExBIO and internal application notes offer practical guidance for integrating PT-100 into experimental designs focused on protein degradation and the tumor microenvironment.